Levetiracetam Solution
Product Images NDC 55154-5782

8 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 55154-5782). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Leve 1)

Chemical Structure (Leve 1)
Chemical structure of levetiracetam, depicting its molecular framework including a pyrrolidone ring and amide functional group, consistent with the active ingredient in the referenced product.*
FDA Label Image

Figure 1 (Leve 2)

Figure 1 (Leve 2)
A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart's y-axis shows the percentage of patients, with bars indicating 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day doses of Levetiracetam.*
FDA Label Image

Figure 2 (Leve 3)

Figure 2 (Leve 3)
A bar chart showing the percentage of patients for three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The chart compares patient response rates across these treatment doses.*
FDA Label Image

Figure 4 (Leve 4)

Figure 4 (Leve 4)
A bar chart comparing the percentage of patients between placebo and Levetiracetam 3000 mg/day groups. The placebo group (N=104) shows 14.4% of patients, while the Levetiracetam 3000 mg/day group (N=180) shows 39.4% of patients. The vertical axis represents the percentage of patients from 0% to 45%.*
FDA Label Image

Figure 4 (Leve 5)

Figure 4 (Leve 5)
A bar chart comparing the percentage of patients in two groups: Placebo (N=97) and Levetiracetam (N=101). The chart shows approximately 19.6% for the placebo group and 44.6% for the Levetiracetam group, illustrating a difference in patient response rates.*
FDA Label Image

Figure 5 (Leve 6)

Figure 5 (Leve 6)
A bar chart comparing the percentage of patients between Placebo (N=51) and Levetiracetam (N=58) groups. The Placebo bar shows 19.6%, while the Levetiracetam bar shows 43.1%, marked with an asterisk indicating statistical significance versus placebo.*
FDA Label Image

Figure 6 (Leve 7)

Figure 6 (Leve 7)
A bar chart comparing the percentage of patients in two groups: Placebo (N=84) and Levetiracetam (N=79). The y-axis represents the percentage of patients, with the Placebo group at 45.2% and the Levetiracetam group at 72.2%. An asterisk marks the Levetiracetam bar indicating statistical significance or emphasis.*
FDA Label Image

500mg/5ml Bag Label (F63f4202 D0c1 4ef3 8dc5 8bb4cab6a613 00)

500mg/5ml Bag Label (F63f4202 D0c1 4ef3 8dc5 8bb4cab6a613 00)
This is a drug information label for Levetiracetam oral solution, USP, with a strength of 500 mg per 5 mL. It specifies that the product is supplied in unit dose cups containing 5 mL each, with each mL providing 100 mg of levetiracetam. The label includes storage instructions, warnings about child resistance and intended use, and contact information for the manufacturer and distributor.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.